ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
428 articles with ImmunoGen Inc.
-
ImmunoGen Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares
10/12/2017
-
ImmunoGen Announces Pricing Of Public Offering Of Common Stock
10/6/2017
-
ImmunoGen Announces Proposed Public Offering Of Common Stock
10/5/2017
-
ImmunoGen Announces Agreements To Exchange $76.4 Million Of Its 4.50% Convertible Senior Notes Due 2021 For Common Stock
9/1/2017
-
ImmunoGen Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference
8/2/2017
-
ImmunoGen Announces Webcast Of Presentation At The Canaccord Genuity Growth Conference
8/2/2017
-
ImmunoGen Reports Recent Progress And Second Quarter 2017 Operating Results
7/28/2017
-
ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2017 Financial Results
7/14/2017
-
ImmunoGen Presents Data From Phase I Study Of IMGN779 In Acute Myeloid Leukemia
6/26/2017
-
ImmunoGen And Sanofi Amend License Agreements
5/30/2017
-
Debiopharm Enters The Field Of Antibody-Drug Conjugates Through Acquisition Of Phase II Asset From ImmunoGen
5/24/2017
-
ImmunoGen Announces New Clinical Data With Mirvetuximab Soravtansine In Ovarian Cancer To Be Presented At 2017 ASCO Annual Meeting
5/18/2017
-
ImmunoGen Reports Recent Progress And First Quarter 2017 Operating Results
5/5/2017
-
ImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer
5/1/2017
-
ImmunoGen Announces Conference Call To Discuss Its First Quarter 2017 Financial Results
4/21/2017
-
ImmunoGen Presents Phase I Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting
3/13/2017
-
ImmunoGen Announces Presentations At AACR Annual Meeting
3/2/2017
-
Why ImmunoGen Investors are Waiting on Bated Breath to Move "FORWARD"
2/22/2017
-
ImmunoGen Reports Recent Progress And Operating Results For Six-Month Period And Quarter Ended December 31, 2016
2/17/2017
-
ImmunoGen Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer
1/27/2017